Literature DB >> 23216938

Chronic fondaparinux use in a hemodialysis patient with heparin-induced thrombocytopenia type II and extracorporeal circuit thrombosis-a case report and review of the literature.

Paula Brown1, Richard Jay, Andrea Fox, Matthew Oliver.   

Abstract

Heparin-induced thrombocytopenia (HIT) is a potentially life-threatening condition that can develop after exposure to unfractionated or low-molecular-weight heparins. Treatment options appear to be limited in patients on concurrent intermittent hemodialysis. We report the case of an 88-year-old man newly initiated on high-flux hemodialysis who developed HIT and extracorporeal circuit thrombosis after 3 weeks of exposure to unfractionated heparin. Our patient was successfully treated with fondaparinux 2.5 mg subcutaneously three times per week and citrate during dialysis sessions. Antifactor Xa levels were measured on several occasions while receiving fondaparinux.
© 2012 The Authors. Hemodialysis International © 2012 International Society for Hemodialysis.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 23216938     DOI: 10.1111/hdi.12003

Source DB:  PubMed          Journal:  Hemodial Int        ISSN: 1492-7535            Impact factor:   1.812


  4 in total

1.  Population pharmacokinetics-pharmacodynamics of fondaparinux in dialysis-dependent chronic kidney disease patients undergoing chronic renal replacement therapy.

Authors:  Danica Michaličková; Jan Miroslav Hartinger; Zuzana Hladinová; Vladimíra Bednářová; Barbora Szonowská; Vladimír Polakovič; Andreas Matthios; Vladimír Tesař; Ondřej Slanař; Elke H J Krekels
Journal:  Eur J Clin Pharmacol       Date:  2021-08-19       Impact factor: 2.953

2.  American Society of Hematology 2018 guidelines for management of venous thromboembolism: heparin-induced thrombocytopenia.

Authors:  Adam Cuker; Gowthami M Arepally; Beng H Chong; Douglas B Cines; Andreas Greinacher; Yves Gruel; Lori A Linkins; Stephen B Rodner; Sixten Selleng; Theodore E Warkentin; Ashleigh Wex; Reem A Mustafa; Rebecca L Morgan; Nancy Santesso
Journal:  Blood Adv       Date:  2018-11-27

3.  Management of heparin-induced thrombocytopenia: systematic reviews and meta-analyses.

Authors:  Rebecca L Morgan; Vahid Ashoorion; Adam Cuker; Housne Begum; Stephanie Ross; Nina Martinez; Beng H Chong; Lori A Linkins; Theodore E Warkentin; Wojtek Wiercioch; Robby Nieuwlaat; Holger Schünemann; Nancy Santesso
Journal:  Blood Adv       Date:  2020-10-27

4.  Fondaparinux: another potential treatment for heparin-induced thrombocytopenia type II?

Authors:  Patrick M Honore; Rita Jacobs; Inne Hendrickx; Elisabeth De Waele; Viola Van Gorp; Herbert D Spapen
Journal:  Crit Care       Date:  2016-01-27       Impact factor: 9.097

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.